DICE Therapeutics Announces Pricing of Upsized Initial Public Offering - Sep 15, 2021

DICE Therapeutics宣布提高首次公开发行的定价-2021年9月15日

2021-09-15 17:30:12 BioSpace

本文共1336个字,阅读需4分钟

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 -- DICE Therapeutics, Inc. , a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares are being offered by DICE. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by DICE, are expected to be $204.0 million. The shares are expected to begin trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol “DICE.” The offering is expected to close on September 17, 2021, subject to the satisfaction of customary closing conditions. In addition, DICE has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. BofA Securities, SVB Leerink and Evercore ISI are acting as joint bookrunning managers for the offering. Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on September 14, 2021. The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@svbleerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474 0200, or by email at ecm.prospectus@evercore.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About DICE Therapeutics, Inc. DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Contact: Katie Engleman, 1AB katie@1abmedia.com
加利福尼亚州南旧金山,2021年9月14日--生物制药公司DICE治疗公司(DICE Therapeutics,Inc.)利用其专有技术平台建立了一条新型口服治疗候选药物管道,以治疗免疫学和其他治疗领域的慢性疾病,今天宣布了其首次公开发行1200万股普通股的定价,公开发行价为每股17.00美元。所有的股票都是以骰子的形式发行的。发行所得款项总额在扣除包销折扣及佣金及DICE应付的其他发行开支前,预计为2.04亿美元。这些股票预计将于2021年9月15日在纳斯达克全球市场开始交易,股票代码为“骰子”。如果满足传统的收盘条件,此次发行预计将于2021年9月17日结束。此外,DICE已授予包销商30天选择权,可按首次公开发行价格减去包销折扣及佣金,额外购买1,800,000股普通股。 美银证券、SVB Leerink和Evercore ISI将担任此次发行的联合簿记管理人。 与这些证券有关的注册声明已向证券交易委员会提交,并于2021年9月14日生效。本次发行仅以招股章程方式进行。最终招股说明书的副本,如有,可向美国银行证券公司索取,地址:NC1-004-03-43,200 North College Street,3楼,夏洛特,北卡罗来纳州28255-0001,注意:招股说明书部,或通过电子邮件dg.ppropectus_requests@BofA.com;SVB Leerink LLC,请注意:辛迪加部门,53道富街,40楼,波士顿,马萨诸塞州02109,或致电(800)808-7525分机。6105,或通过电子邮件发送到syndicate@svbleerink.com;或Evercore Group L.L.C.,请注意:Equity Capital Markets,55 East 52 Street,35楼,NY New York,10055,电话:(888)474 020 0,或电子邮件:ecm.pprotus@Evercore.com。 本新闻稿不构成出售要约或邀请购买要约,也不应在任何州或其他司法管辖区内出售这些证券,而在根据任何此类州或司法管辖区的证券法注册或资格之前,此类要约、邀请或出售将是非法的。 关于骰子治疗公司。 DICE Therapeutics公司是一家生物制药公司,利用其专有技术平台,建立新型口服治疗候选药物的管道,以治疗免疫学和其他治疗领域的慢性疾病。DICE最初专注于开发针对免疫学中有效靶点的口服疗法,目标是实现与系统生物学对应物相当的效力,这些系统生物学对应物在这些疾病领域显示出迄今为止最大的治疗效益。该公司的DELSCAPE平台旨在发现选择性口服小分子,这些小分子具有像全身生物制剂一样有效地调节蛋白质-蛋白质相互作用的潜力。DICE的主要治疗候选药物S011806,是一种促炎信号分子白细胞介素17(IL-17)的口服拮抗剂,白细胞介素17(IL-17)是一个与多种免疫学适应症相关的有效药物靶点。DICE还在开发针对α4://7整合素和αV://1/αV://6整合素的口服治疗候选药物,分别用于治疗炎症性肠病和特发性肺纤维化。 联系人: 凯蒂·恩格莱曼,1AB @1abmedia.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文